Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

Remember oligodendrocytes: Uncovering their overlooked role in Alzheimer's disease

Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.

Signaling Pathways Regulating Neuron–glia Interaction and Their Implications in Alzheimer's Disease

Oligodendrocytes and Alzheimer's disease

Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation

Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's Disease

Recognizing Alzheimer's disease from perspective of oligodendrocytes: Phenomena or pathogenesis?

Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology

F2‐01‐01: Oligodendrocyte‐Enriched Gene Networks Reveal Novel Pathways and Key Targets in the Pathogenesis of Alzheimer’s Disease

Multiscale Network Modeling of Oligodendrocytes Reveals Molecular Components of Myelin Dysregulation in Alzheimer's Disease.

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease

The Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage

Proteomic insights into early-stage Alzheimer's disease: Identifying key neuronal proteins impacted by amyloid beta oligomers in an in vitro model

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target

Oligodendrocytes and myelin: Active players in neurodegenerative brains?

Oligomeric amyloid beta prevents myelination in a clusterin-dependent manner

Oligodendrocytes Play a Critical Role in White Matter Damage of Vascular Dementia